1. Home
  2. MSDL vs TMDX Comparison

MSDL vs TMDX Comparison

Compare MSDL & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MSDL
  • TMDX
  • Stock Information
  • Founded
  • MSDL 2019
  • TMDX 1998
  • Country
  • MSDL United States
  • TMDX United States
  • Employees
  • MSDL N/A
  • TMDX N/A
  • Industry
  • MSDL
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • MSDL
  • TMDX Health Care
  • Exchange
  • MSDL NYSE
  • TMDX Nasdaq
  • Market Cap
  • MSDL 1.9B
  • TMDX 2.1B
  • IPO Year
  • MSDL N/A
  • TMDX 2019
  • Fundamental
  • Price
  • MSDL $21.61
  • TMDX $56.73
  • Analyst Decision
  • MSDL Buy
  • TMDX Buy
  • Analyst Count
  • MSDL 7
  • TMDX 11
  • Target Price
  • MSDL $21.67
  • TMDX $116.10
  • AVG Volume (30 Days)
  • MSDL 354.2K
  • TMDX 2.6M
  • Earning Date
  • MSDL 01-01-0001
  • TMDX 02-24-2025
  • Dividend Yield
  • MSDL 9.25%
  • TMDX N/A
  • EPS Growth
  • MSDL N/A
  • TMDX N/A
  • EPS
  • MSDL N/A
  • TMDX 0.94
  • Revenue
  • MSDL N/A
  • TMDX $401,090,000.00
  • Revenue This Year
  • MSDL $1,597.39
  • TMDX $81.61
  • Revenue Next Year
  • MSDL $15.28
  • TMDX $22.52
  • P/E Ratio
  • MSDL N/A
  • TMDX $60.54
  • Revenue Growth
  • MSDL N/A
  • TMDX 109.09
  • 52 Week Low
  • MSDL $19.05
  • TMDX $55.00
  • 52 Week High
  • MSDL $24.18
  • TMDX $177.37
  • Technical
  • Relative Strength Index (RSI)
  • MSDL 62.87
  • TMDX 35.29
  • Support Level
  • MSDL $20.23
  • TMDX $58.40
  • Resistance Level
  • MSDL $21.17
  • TMDX $67.80
  • Average True Range (ATR)
  • MSDL 0.35
  • TMDX 4.65
  • MACD
  • MSDL 0.07
  • TMDX -0.46
  • Stochastic Oscillator
  • MSDL 94.85
  • TMDX 6.32

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: